• 1
    Kydd JH, Townsend HG, Hannant D. The equine immune response to equine herpesvirus-1: The virus and its vaccines. Vet Immunol Immunopathol 2006;111:1530.
  • 2
    Slater JD, Lunn DP, Horohov DW, et al. Report of the equine herpesvirus-1 Havermeyer Workshop, San Gimignano, Tuscany, June 2004. Vet Immunol Immunopathol 2006;111:313.
  • 3
    Allen GP, Kydd JH, Slater JD, et al. Equid herpesvirus 1 and equid herpesvirus 4 infections. In: CoetzerJAW, TustinRC, eds. Infectious Diseases of Livestock, 1st ed. Newmarket: Oxford University Press; 2004:829859.
  • 4
    Slater J. Equine herpesviruses. In: SellonDC, LongMT, eds. Equine Infectious Diseases. St. Louis: Saunders Elsevier; 2007:134152.
  • 5
    Foote CE, Love DN, Gilkerson JR, et al. Detection of EHV-1 and EHV-4 DNA in unweaned Thoroughbred foals from vaccinated mares on a large stud farm. Equine Vet J 2004;36:341345.
  • 6
    USDA, APHIS, VS, CEAH. Equine herpesvirus myeloencephalopathy: a potentially emerging disease, 2007. Available at: Accessed December 9, 2008.
  • 7
    Kydd JH, Smith KC, Hannant D, et al. Distribution of equid herpesvirus-1 (EHV-1) in respiratory tract associated lymphoid tissue: implications for cellular immunity [see comments]. Equine Vet J 1994;26:470473.
  • 8
    Goehring LS, Van Winden SC, Van Maanen C, et al. Equine herpesvirus type 1-associated myeloencephalopathy in The Netherlands: A four-year retrospective study (1999–2003). J Vet Intern Med 2006;20:601607.
  • 9
    Smith KC, Borchers K. A study of the pathogenesis of equid herpesvirus-1 (EHV-1) abortion by DNA in-situ hybridization. J Comp Pathol 2001;125:304310.
  • 10
    Smith KC, Whitwell KE, Blunden AS, et al. Equine herpesvirus-1 abortion: Atypical cases with lesions largely or wholly restricted to the placenta. Equine Vet J 2004;36:7982.
  • 11
    Smith KC, Mumford JA, Lakhani K. A comparison of equid herpesvirus-1 (EHV-1) vascular lesions in the early versus late pregnant equine uterus. J Comp Pathol 1996;114:231247.
  • 12
    Allen GP. Risk factors for development of neurologic disease after experimental exposure to equine herpesvirus-1 in horses. Am J Vet Res 2008;69:15951600.
  • 13
    Smith D, Hamblin A, Edington N. Equid herpesvirus 1 infection of endothelial cells requires activation of putative adhesion molecules: An in vitro model. Clin Exp Immunol 2002;129:281287.
  • 14
    Smith DJ, Hamblin AS, Edington N. Infection of endothelial cells with equine herpesvirus-1 (EHV-1) occurs where there is activation of putative adhesion molecules: A mechanism for transfer of virus. Equine Vet J 2001;33:138142.
  • 15
    Nugent J, Birch-Machin I, Smith KC, et al. Analysis of equid herpesvirus 1 strain variation reveals a point mutation of the DNA polymerase strongly associated with neuropathogenic versus nonneuropathogenic disease outbreaks. J Virol 2006;80:40474060.
  • 16
    Mumford JA, Hannant D, Jessett DM, et al. Abortigenic and neurological disease caused by experimental infection with equid herpesvirus-1. In: NakajimaH, PlowrightW, eds. Equine Infectious Diseases, Vol. VII. Newmarket: R&W Publications Ltd; 1994:261277.
  • 17
    Allen GP, Breathnach CC. Quantification by real-time PCR of the magnitude and duration of leucocyte-associated viraemia in horses infected with neuropathogenic vs. non-neuropathogenic strains of EHV-1. Equine Vet J 2006;38:252257.
  • 18
    Goodman LB, Loregian A, Perkins GA, et al. A point mutation in a herpesvirus polymerase determines neuropathogenicity. PLoS Pathog 2007;3:e160.
  • 19
    Goodman LB, Wagner B, Flaminio MJ, et al. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1). Vaccine 2006;24:36363645.
  • 20
    Frampton AR Jr., Stolz DB, Uchida H, et al. Equine herpesvirus 1 enters cells by two different pathways, and infection requires the activation of the cellular kinase ROCK1. J Virol 2007;81:1087910889.
  • 21
    Paillot R, Daly JM, Luce R, et al. Frequency and phenotype of EHV-1 specific, IFN-gamma synthesising lymphocytes in ponies: The effects of age, pregnancy and infection. Dev Comp Immunol 2007;31:202214.
  • 22
    Telford EA, Watson MS, McBride K, et al. The DNA sequence of equine herpesvirus-1. Virology 1992;189:304316.
  • 23
    Gilkerson JR, Whalley JM, Drummer HE, et al. Epidemiological studies of equine herpesvirus 1 (EHV-1) in thoroughbred foals: A review of studies conducted in the Hunter Valley of New South Wales between 1995 and 1997. Vet Microbiol 1999;68:1525.
  • 24
    Gilkerson JR, Whalley JM, Drummer HE, et al. Epidemiology of EHV-1 and EHV-4 in the mare and foal populations on a Hunter Valley stud farm: Are mares the source of EHV-1 for unweaned foals? Vet Microbiol 1999;68:2734.
  • 25
    Foote CE, Gilkerson JR, Whalley JM, et al. Seroprevalence of equine herpesvirus 1 in mares and foals on a large Hunter Valley stud farm in years pre- and postvaccination. Aust Vet J 2003;81:283288.
  • 26
    Edington N, Welch HM, Griffiths L. The prevalence of latent equid herpesviruses in the tissues of 40 abattoir horses. Equine Vet J 1994;26:140142.
  • 27
    Allen GP. Antemortem detection of latent infection with neuropathogenic strains of equine herpesvirus-1 in horses. Am J Vet Res 2006;67:14011405.
  • 28
    Yactor J, Lunn KF, Traub-Dargatz J, et al. Detection of nasal shedding of EHV-1 & 4 at equine show events and sales by multiplex real-time PCR. In: American Association of Equine Practitioners 52nd Annual Convention, San Antonio, Texas, 2006;223–227.
  • 29
    Wang L, Raidal SL, Pizzirani A, et al. Detection of respiratory herpesviruses in foals and adult horses determined by nested multiplex PCR. Vet Microbiol 2007;121:1828.
  • 30
    Brown JA, Mapes S, Ball BA, et al. Prevalence of equine herpesvirus-1 infection among Thoroughbreds residing on a farm on which the virus was endemic. J Am Vet Med Assoc 2007;231:577580.
  • 31
    Pusterla N, Mapes S, Wilson WD. Use of viral loads in blood and nasopharyngeal secretions for the diagnosis of EHV-1 infection in field cases. Vet Rec 2008;162:728729.
  • 32
    Allen GP, Bolin DC, Bryant U, et al. Prevalence of latent, neuropathogenic equine herpesvirus-1 in the Thoroughbred broodmare population of central Kentucky. Equine Vet J 2008;40:105110.
  • 33
    Greenwood RE, Simson AR. Clinical report of a paralytic syndrome affecting stallions, mares and foals on a Thoroughbred studfarm. Equine Vet J 1980;12:113117.
  • 34
    Friday PA, Scarratt WK, Elvinger F, et al. Ataxia and paresis with equine herpesvirus type 1 infection in a herd of riding school horses. J Vet Intern Med 2000;14:197201.
  • 35
    Henninger RW, Reed SM, Saville WJ, et al. Outbreak of neurologic disease caused by equine herpesvirus-1 at a university equestrian center. J Vet Intern Med 2007;21:157165.
  • 36
    Van Maanen C, Sloet van Oldruitenborgh-Oosterbaan MM, Damen EA, et al. Neurological disease associated with EHV-1-infection in a riding school: Clinical and virological characteristics. Equine Vet J 2001;33:191196.
  • 37
    Van Der Meulen K, Vercauteren G, Nauwynck H, et al. A local epidemic of equine herpesvirus-1 induced neurological disorders in Belgium. Vlaams Diergeneeskundig Tijdschrift 2003;72:366372.
  • 38
    Studdert MJ, Hartley CA, Dynon K, et al. Outbreak of equine herpesvirus type 1 myeloencephalitis: New insights from virus identification by PCR and the application of an EHV-1-specific antibody detection ELISA. Vet Rec 2003;153:417423.
  • 39
    Pusterla N, Mapes S, Wilson WD. Diagnostic sensitivity of nasopharyngeal and nasal swabs for the molecular detection of EHV-1. Vet Rec 2008;162:520521.
  • 40
    Anon. American Association of Equine Practitioners Guidelines on Infectious Disease Outbreak Control, 2006. Available at: Accessed December 9, 2008.
  • 41
    Diallo IS, Hewitson G, Wright L, et al. Detection of equine herpesvirus type 1 using a real-time polymerase chain reaction. J Virol Methods 2005;131:9298.
  • 42
    Hussey SB, Clark R, Lunn KF, et al. Detection and quantification of equine herpesvirus-1 viremia and nasal shedding by real-time polymerase chain reaction. J Vet Diagn Invest 2006;18:335342.
  • 43
    Allen GP. Development of a real-time polymerase chain reaction assay for rapid diagnosis of neuropathogenic strains of equine herpesvirus-1. J Vet Diagn Invest 2007;19:6972.
  • 44
    Drummer HE, Reynolds A, Studdert MJ, et al. Application of an equine herpesvirus 1 (EHV1) type-specific ELISA to the management of an outbreak of EHV1 abortion. Vet Rec 1995;136:579581.
  • 45
    Edington N, Bridges CG, Patel JR. Endothelial cell infection and thrombosis in paralysis caused by equid herpesvirus-1: Equine stroke. Arch Virol 1986;90:111124.
  • 46
    Edington N, Smyth B, Griffiths L. The role of endothelial cell infection in the endometrium, placenta and foetus of equid herpesvirus 1 (EHV-1) abortions. J Comp Pathol 1991;104:379387.
  • 47
    Kydd JH, Wattrang E, Hannant D. Pre-infection frequencies of equine herpesvirus-1 specific, cytotoxic T lymphocytes correlate with protection against abortion following experimental infection of pregnant mares. Vet Immunol Immunopathol 2003;96:207217.
  • 48
    Breathnach CC, Yeargan MR, Sheoran AS, et al. The mucosal humoral immune response of the horse to infective challenge and vaccination with equine herpesvirus-1 antigens. Equine Vet J 2001;33:651657.
  • 49
    Luce R, Shepherd M, Paillot R, et al. Equine herpesvirus-1-specific interferon gamma (IFNgamma) synthesis by peripheral blood mononuclear cells in thoroughbred horses. Equine Vet J 2007;39:202209.
  • 50
    Rosas CT, Goodman LB, Von Einem J, et al. Equine herpesvirus type 1 modified live virus vaccines: Quo vaditis? Expert Rev Vaccines 2006;5:119131.
  • 51
    Dutta SK, Shipley WD. Immunity and the level of neutralization antibodies in foals and mares vaccinated with a modified live-virus rhinopneumonitis vaccine. Am J Vet Res 1975;36:445448.
  • 52
    Mitchell D. Vaccines for EHV-1 abortion. Vet Rec 1983;112:285.
  • 53
    Bryans JT, Allen GP. Application of a chemically inactivated, adjuvanted vaccine to control abortigenic infection of mares by equine herpesvirus I. Dev Biol Stand 1982;52:493498.
  • 54
    Burrows R, Goodridge D, Denyer MS. Trials of an inactivated equid herpesvirus 1 vaccine: Challenge with a subtype 1 virus. Vet Rec 1984;114:369374.
  • 55
    Burki F, Rossmanith W, Nowotny N, et al. Viraemia and abortions are not prevented by two commercial equine herpesvirus-1 vaccines after experimental challenge of horses. Vet Q 1990;12:8086.
  • 56
    Ostlund EN. The equine herpesviruses. Vet Clin North Am Equine Pract 1993;9:283294.
  • 57
    Anon. American Association of Equine Practitioners Guidelines on Vaccination, 2007. Available at: Accessed December 9, 2008.
  • 58
    Van Der Meulen KM, Favoreel HW, Pensaert MB, et al. Immune escape of equine herpesvirus 1 and other herpesviruses of veterinary importance. Vet Immunol Immunopathol 2006;111:3140.
  • 59
    Koppers-Lalic D, Reits EA, Ressing ME, et al. Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing. Proc Natl Acad Sci USA 2005;102:51445149.
  • 60
    Allen GP. Epidemic disease caused by equine herpesvirus-1: Recommendations for prevention and control. Equine Vet Educ 2002;4:177183.
  • 61
    Goehring L, Lunn DP. Equine herpesvirus myeloencephalopathy. In: RobinsonNE, SprayberryK, eds. Current Therapy in Equine Medicine, 6th ed. St. Louis: Saunders; 2008:177181.
  • 62
    Ziebell KL, Steinmann H, Kretzdorn D, et al. The use of Baypamun N in crowding associated infectious respiratory disease: Efficacy of Baypamun N (freeze dried product) in 4–10 month old horses. Zentralblatt Fuer Veterinaermedizin Reihe B 1997;44:529536.
  • 63
    Garre B, Van Der Meulen K, Nugent J, et al. In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet. Vet Microbiol 2007;122:4351.
  • 64
    Keller PM, Fyfe JA, Beauchamp L, et al. Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities. Biochem Pharmacol 1981;30:30713077.
  • 65
    Bentz BG, Maxwell LK, Erkert RS, et al. Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses. J Vet Intern Med 2006;20:589594.
  • 66
    Maxwell LK, Bentz BG, Bourne DW, et al. Pharmacokinetics of valacyclovir in the adult horse. J Vet Pharmacol Ther 2008;31:312320.
  • 67
    Garre B, Shebany K, Gryspeerdt A, et al. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. Antimicrob Agents Chemother 2007;51:43084314.